



10-26-06

IFW

Express Mail No. EV532862408US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: ZELDIS

Confirmation No.: TBA

Application No: 10/576,138 ✓

Group Art Unit: TBA

Filed: April 14, 2006

Examiner: TBA

For: METHODS AND COMPOSITIONS USING  
THALIDOMIDE FOR THE TREATMENT  
AND MANAGEMENT OF CANCERS AND  
OTHER DISEASES

Attorney Docket No.: 9516-352-999  
(CAM: 501872-999350)

**INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicant hereby directs the Examiner's attention to References **A01-A85**, **B01-B07** and **C01-C179**, listed on the attached Substitute For form 1449/PTO entitled "List of References Cited by Applicant." (References A01-A85 are not being submitted pursuant to 37.C.F.R. § 1.98(a)(2)(ii), unless requested by the Office.)

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.


This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due. Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: October 24, 2006

  
Yeansil Moon 52,042  
(Reg. No.)  
For: Anthony M. Insogna 35,203  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, NY 10017  
(212) 326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

ATTY DOCKET NO.  
9516-352-999  
(501872-999350)

APPLICATION NO  
10/576,138

APPLICANT  
Zeldis

FILING DATE  
April 14, 2006

GROUP

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A01	60/499,723		Markian	
A02	60/372,348		Hariri et al.	
A03	10/732,867		D'Amato et al.	
A04	09/545,654		D'Amato	
A05	09/287,377		D'Amato	
A06	2004/0122052	6/24/2004	Muller, George et al.	
A07	2004/0091455	5/13/2004	Zeldis, Jerome B.	
A08	2004/0087546	5/6/2004	Zeldis, Jerome B.	
A09	2004/0077686	4/22/2004	Dannenberg, Andrew J. et al.	
A10	2004/0077685	4/22/2004	Figg, William D. et al.	
A11	2004/0029832	2/12/2004	Zeldis, Jerome B.	
A12	2003/0235909	12/25/2003	Hariri, Robert J. et al.	
A13	2003/0191098	10/9/2003	D'Amato, Robert J.	
A14	2003/0187024	10/2/2003	D'Amato, Robert	
A15	2003/0181428	9/25/2003	Green, Shawn J. et al.	
A16	2003/0144325	7/31/2003	Muller, George W. et al.	
A17	2003/0139451	7/24/2003	Shah, Jamshed H. et al.	
A18	2003/0096841	5/22/2003	Robarge et al.	
A19	2003/0069428	4/10/2003	Muller, George et al.	
A20	2003/0045552	3/6/2003	Robarge et al.	
A21	2003/0028028	2/6/2003	Man, Hon-Wah et al.	
A22	2003/0013739	1/16/2003	Masferrer et al.	
A23	2002/0183360	12/5/2002	Muller, George W. et al.	
A24	2002/0173658	11/21/2002	Muller, George W. et al.	
A25	2002/0161023	10/31/2002	D'Amato, Robert	
A26	2002/0128228	9/12/2002	Hwu	
A27	2002/0061923	5/23/2002	D'Amato, Robert	
A28	2002/0054899	5/9/2002	Zeldis, Jerome B.	
A29	2002/0052398	5/2/2002	D'Amato, Robert J.	
A30	2002/0045643	4/18/2002	Muller et al.	
A31	2002/0035090	3/21/2002	Zeldis et al.	
A32	2001/0056114	12/27/2001	D'Amato, Robert	
A33	2001/0018445	8/30/2001	Huang et al.	
A34	6,555,554	4/29/2003	Muller et al.	
A35	6,518,298	2/11/2003	Green et al.	

	A36	6,476,052	11/5/2002	Muller et al.	
	A37	6,469,045	10/22/2002	D'Amato	
	A38	6,458,810	10/1/2002	Muller et al.	
	A39	6,420,414	7/16/2002	D'Amato	
	A40	6,403,613	6/11/2002	Man et al.	
	A41	6,395,754	5/28/2002	Muller et al.	
	A42	6,380,239	4/30/2002	Muller et al.	
	A43	6,335,349	1/1/2002	Muller et al.	
	A44	6,326,388	12/4/2001	Man et al.	
	A45	6,316,471	11/13/2001	Muller et al.	
	A46	6,281,230	8/28/2001	Muller et al.	
	A47	6,235,756	5/22/2001	D'Amato	
	A48	6,140,346	10/31/2000	Andrulis, Jr. et al.	
	A49	6,114,355	9/5/2000	D'Amato	
	A50	6,071,948	6/6/2000	D'Amato	
	A51	6,020,358	2/1/2000	Muller et al.	
	A52	5,955,476	9/21/1999	Muller et al.	
	A53	5,929,117	7/27/1999	Muller et al.	
	A54	5,877,200	3/2/1999	Muller	
	A55	5,874,448	2/23/1999	Muller et al.	
	A56	5,798,368	8/25/1998	Muller et al.	
	A57	5,733,566	3/31/1998	Lewis	
	A58	5,731,325	3/24/1998	Andrulis, Jr. et al.	
	A59	5,712,291	1/27/1998	D'Amato	
	A60	5,698,579	12/16/1997	Muller	
	A61	5,674,533	10/7/1997	Santus et al.	
	A62	5,639,476	6/17/1997	Oshlack et al.	
	A63	5,635,517	6/3/1997	Muller et al.	
	A64	5,629,327	5/13/1997	D'Amato	
	A65	5,593,990	1/14/1997	D'Amato	
	A66	5,591,767	1/7/1997	Mohr et al.	
	A67	5,580,755	12/3/1996	Souza	
	A68	5,528,823	6/25/1996	Rudy, Jr. et al.	
	A69	5,393,870	2/28/1995	Deeley et al.	
	A70	5,391,485	2/21/1995	Deeley et al.	
	A71	5,385,901	1/31/1995	Kaplan et al.	
	A72	5,354,556	10/11/1994	Sparks et al.	
	A73	5,229,496	7/20/1993	Deeley et al.	
	A74	5,134,127	7/28/1992	Stella et al.	
	A75	5,120,548	6/9/1992	McClelland et al.	
	A76	5,073,543	12/17/1991	Marshall et al.	
	A77	5,059,595	10/22/1991	Le Grazie	
	A78	4,999,291	3/12/1991	Souza	
	A79	4,810,643	3/7/1989	Souza	
	A80	4,008,719	2/22/1977	Theeuwes et al.	

	A81	3,916,899	11/4/1975	Theeuwes et al.	
	A82	3,845,770	11/5/1974	Theeuwes et al.	
	A83	3,598,123	8/10/1971	Zaffaroni et al.	
	A84	3,536,809	10/27/1970	Applezweig	
	A85	2004/0266809	12/30/2004	Emanuel et al.	

### FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B01	WO 03/086373 PCT	10/23/2003				
	B02	WO 02/064083 PCT	08/22/2002				
	B03	WO 02/059106 PCT	08/01/2002				
	B04	WO 01/70275 PCT	09/27/2001				
	B05	WO 01/087307 PCT	11/22/2001				
	B06	WO 98/54170 PCT	12/03/1998				
	B07	WO 98/03502 PCT	01/29/1998				

### NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published, etc.)

*EXAMINER INITIAL		
C01	CARTENSEN, 1995, <i>Drug Stability: Principles &amp; Practice</i> , 2 <sup>nd</sup> ed., Marcel Dekker, New York, NY pp. 379-380	
C02	CORRAL et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," <i>Ann. Rheum. Dis.</i> 58(Suppl 1):1107-113	
C03	CRAIG et al., 1967, "Potential anticancer agents. III. 2-phthalimidoaldehydes and derivatives," <i>Potential Anticancer Agents III</i> 10:1071-1073	
C04	D'AMATO et al., 2001, "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma," <i>Semin. Oncol.</i> 28:597-601	
C05	D'AMATO et al., 1994, "Thalidomide is an Inhibitor of Angiogenesis", <i>Proc. Natl. Acad. Sci.</i> 91:4082-4085	
C06	DE et al., 1976, "Hansch analysis for some antineoplastic glutarimides," <i>J. Indian Chem. Soc. I.III:</i> 825-826	
C07	DE et al., 1976, "Possible antineoplastic agents: III. Synthesis of 6-alkyl-2-[4'-methoxyphthalimido] and 6-alkyl-3-[3'-4'-dimethoxyphenyl] glutarimides," <i>J. Indian Chem. Soc. I.III:</i> 1122-1125	
C08	DREDGE et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," <i>Br. J. Cancer</i> 87(10):1166-1172	
C09	FOLKMAN et al., 1983, "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone," <i>Science</i> 221(4612):719-725	
C10	GERSHBEIN, 1991, "The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas," <i>Cancer Letters</i> 60: 129-133	
C11	GRABSTALD et al., 1965, "Clinical experiences with thalidomide in patients with cancer," <i>Clinical Pharmacology and Therapeutics</i> 6:298-302	
C12	LENTZSCH et al., 2003, "Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo," <i>Leukemia</i> 17(1):41-44	
C13	LENTZSCH et al., 2002, "S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice", <i>Cancer Research</i> 62:2300-2305	
C14	MIYACHI et al., 1997, "Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity," <i>J. Med. Chem.</i> 40:2858-2865	
C15	MULLER et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," <i>Bioorg. Med. Chem. Lett.</i> 9(11):1625-1630	
C16	MULLER et al., 1998, "Thalidomide analogs and PDE4 inhibition," <i>Bioorg. Med. Chem. Lett.</i> 8(19):2669-2674	
C17	MULLER et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," <i>J. Med. Chem.</i> 39(17):3238-3240	
C18	OLSON et al., 1965, "Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer," <i>Clinical Pharmacology and Therapeutics</i> 6(3):292-297	

C19	PENICHET et al., 2001, "Antibody-cytokine fusion proteins for the therapy of cancer," <i>J. Immunol. Methods</i> 248(1-2):91-101
C20	<i>Physician's Desk Reference</i> , 2002, 56 <sup>th</sup> ed., pp. 1755-1760
C21	RAZA et al., 2001, "Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes," <i>Blood</i> 98(4):958-965
C22	SHAH et al., 1999, "Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis," <i>J. Med. Chem.</i> 42:3014-3017
C23	SHIBATA et al., 1995, "N-alkylphthalimides: structural requirement of thalidomidal action on 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor $\alpha$ production by human leukemia HL-60 cells," <i>Chem. Pharm. Bull.</i> 43(1):177-179
C24	SHIMAZAWA et al., 1999, "Antiangiogenic activity of tumor necrosis factor- $\alpha$ production regulators derived from thalidomide," <i>Biol. Pharm. Bull.</i> 22(2):224-226
C25	BALANT et al., 1995, "Metabolic Considerations in Prodrug Design," <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5 <sup>th</sup> ed., pp 949-982
C26	WILEN et al., 1977, <i>Tetrahedron</i> 33:2725
C27	WILEN, 1972, <i>Tables of Resolving Agents and Optical Resolutions</i> , E.L. Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN pp. 268
C28	WOLFF ed., 1995, <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5 <sup>th</sup> ed., pp. 172-178
C29	N. AKE JOHNSON, 1972, "Chemical Structure and Teratogenic Properties," <i>Acta Pharm.</i> pp. 521-542.
C30	ALEXANIAN et al., 2004, "VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma," <i>Am. Soc. Hematol.</i> 46 <sup>th</sup> Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #210
C31	ANDERSON, 2000, "Thalidomide: Therapeutic potential in hematologic malignancies," <i>Seminars in Hematology</i> 37(1 Supp 3): 1-4
C32	ATTAL et al., 2004, "Maintenance treatment with thalidomide after autologous transplantation for myeloma: First analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02)," <i>Am. Soc. Hematol.</i> 46 <sup>th</sup> Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #535
C33	BERNARDESCHI et al., 2003, <i>J. Exp. Clin. Cancer Res.</i> 22(4):129-133
C34	CORRAL et al., 1999, "Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha," <i>J. Immunol.</i> 163(1):380-386
C35	DAVIES et al., 2001, "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma," <i>Blood</i> 98(1):210-216
C36	DIMOPOULOS et al., 2004, "Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma $\geq$ 75 years of age," <i>Am. Soc. Hematol.</i> 46 <sup>th</sup> Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #1482
C37	EISEN et al., 2000, "Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer," <i>Br. J. Cancer</i> 82(4):812-817
C38	FAKHOURI et al., 2004, "Thalidomide in patients with multiple myeloma and renal failure," <i>Br. J. Haematol.</i> 125:96-97
C39	FENK et al., 2005, "Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma," <i>Leukemia</i> 19(1):156-159
C40	GUPTA et al., 2001, "Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications," <i>Leukemia</i> 15(12):1950-1961
C41	HASLETT et al., 2003, "Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro," <i>J. Infect. Dis.</i> 187(6):946-955
C42	HIDESHIMA et al., 2000, "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy," <i>Blood</i> 96(9):2943-2950
C43	OFFIDANI et al., 2003, Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. <i>Haematologica</i> . 2003 Dec;88(12):1432-1433
C44	PALUMBO et al., 2004, "A prospective randomized trial of oral melphalan prednisone, thalidomide (MPT) vs. oral melphalan, prednisone (MP): An interim analysis," <i>Am. Soc. Hematol.</i> 46 <sup>th</sup> Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #207
C45	RAJE et al., 1999, "Thalidomide--a revival story," <i>N. Engl. J. Med.</i> 341(21):1606-1609
C46	RAJKUMAR et al., 2004, "Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): Results of a phase III trial coordinated by the Eastern Cooperative Oncology Group," <i>Am. Soc. Hematol.</i> 46 <sup>th</sup> Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #205
C47	RAJKUMAR et al., 2000, "Prognostic value of bone marrow angiogenesis in multiple myeloma," <i>Clin. Cancer Res.</i> 6(8):3111-3116
C48	RIBATTI et al., 1999, "Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma," <i>Br. J. Cancer</i> 79(3-4):451-455
C49	SINGHAL et al., 1999, Antitumor activity of thalidomide in refractory multiple myeloma," <i>N. Engl. J. Med.</i> 341(21):1565-1571
C50	STEINS et al., 2002, "Efficacy and safety of thalidomide in patients with acute myeloid leukemia," <i>Blood</i> 99(3):834-839
C51	VACCA et al., 1999, "Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma," <i>Blood</i> 93(9):3064-3073

	C52	WOHRER et al., 2004, "Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report," <i>Hematol. J.</i> 5(4):361-363
	C53	BACH, 1963, "Thalidomide in Cancer Chemotherapy," <i>The Lancet</i> , No. 1271, pg. 71
	C54	BACH, 1963, "Studies on the Possible Anti-Neoplastic Effect of Thalidomide," <i>Acta Pathologica Et Microbiologica Scandinavica</i> 59:491-499
	C55	CHAUNDHRY, 1966, <i>Cancer Research</i> , "Effect of Prednisolone and Thalidomide on Induced Submandibular Gland Tumors in Hamster," 26(part 1)1884-86
	C56	DIPAOLO, 1963, "Effect of Thalidomide on a Variety of Transplantable Tumors," <i>Cancer Chemotherapy Reports</i> No. 29, p. 99-102
	C57	DIPAOLO, 1963, "In vitro Test Systems for Cancer Chemotherapy, II. Correlation of in vitro Inhibition of Dehydrogenase and Growth with in vivo Inhibition of Ehrlich Asoites Tumor," <i>Proceedings of the Society for Experimental Biology &amp; Medicine</i> , 114:384-387
	C58	DIPAOLO, 1964, "Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro" <i>Science</i> 144:1583
	C59	MAUAD, 1963, "Clinical Improvements Obtained in Advanced Cancer Patients with Treatment with Thalidomide Associated with Hormones," <i>Anais Paulistas de Medicina e Cirurgia</i> 86:13-40
	C60	ROE and MITCHLEY, 1963, "Thalidomide and Neoplasia" <i>Nature</i> 200:1016-1017
	C61	LIU et al., "Phase I study of CC-5013 (Revimid), a thalidomide derivative, in patients with refractory metastatic cancer," <i>American Society of Clinical Oncology, Abstract #927</i> , 2003.
	C62	ZANGARI et al., "Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT)," <i>American Society of Hematology, Abstract #3226</i> , 2001.
	C63	ZELDIS et al., "Update on the evolution of the IMiD™," <i>International Society for Biological Therapy of Cancer, Oral Abstract</i> , 2003.
	C64	ANDERSON, "Moving disease biology from the laboratory to the clinic," <i>Seminars in Oncology</i> , 2002, 29:17-20
	C65	BARLOGIE et al., "Total Therapy II (TTII) for newly diagnosed multiple myeloma (MM): preliminary data on feasibility and efficacy in the first 231 enrolled patients; comparison with predecessor trial total therapy I ((TTI) (N=231)," <i>Blood, Abstract # 2857</i> , Dec. 7-11, 2001, <i>American Society of Hematology</i>
	C66	BARLOGIE et al., "High-dose therapy immunomodulatory drugs in multiple myeloma," <i>Seminars in Oncology</i> , 2002, 29 (6):26-33
	C67	BARLOGIE et al., "Introduction: Thalidomide and the IMiDs in multiple myeloma," <i>Seminars in Hematology</i> , 2003, 40 (4):1-2
	C68	BARLOGIE, "Thalidomide and CC-5013 in Multiple Myeloma: The University of Arkansas experience," <i>Seminars in Hematology</i> , 2003, 40 (4):33-38
	C69	BARTLETT et al., "The evolution of thalidomide and its IMiD derivatives as anticancer agents," <i>Nature Reviews Cancer</i> , 2004, 4 (4):1-9
	C70	BARTLETT et al., "Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers," <i>British Journal of Cancer</i> , 2004, 90:955-961
	C71	BATTEGAY, "Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects," <i>J. Mol. Med.</i> , 1995, 73:333-346
	C72	BAZ et al., "Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and revlimid (R) (DVd-R) results in a high response rate in patients with refractory multiple myeloma (RMM)," <i>Blood, Abstract # 2559, American Society of Hematology</i> , December 10-13, 2005
	C73	BRENNEN et al., "Thalidomide and analogues: current proposed mechanisms and therapeutic usage," <i>Clinical Prostate Cancer</i> , 2004, 3 (1):54-61
	C74	CELGENE CORPORATION, "Celgene advances immunomodulatory drug (IMiD™) clinical program," Press Release, February 2000
	C75	CELGENE CORPORATION, "Initial Phase I solid tumor data on Celgene's lead IMiD™, Revimid™," Press Release, June 2001
	C76	CELGENE CORPORATION, "Celgene Corporation receives orphan drug designation for Revimid™ for multiple myeloma," Press Release, October 2001
	C77	CELGENE CORPORATION, "Celgene Corporation announces third quarter results. Thalomid® (thalidomide) sales increase 24%. Prescriptions up 50%. Enhanced S.T.E.P.S.® launched. Pilot d-MPH data presented," Press Release, October 2001
	C78	CELGENE CORPORATION, "Celgene expands clinical development program for Revimid™. Five additional trials of Revimid initiated in hematological and solid tumor cancers," Press Release, June 2002
	C79	CELGENE CORPORATION, "Celgene Corporation announces third quarter results. THALOMID® (thalidomide) revenue increases 41% to \$30.5 million. Pivotal programs for THALOMID and REVIMID™ finalized. Peer-reviewed publications of THALOMID and REVIMID data. First JNK inhibitor advanced to Phase I clinical trial," Press Release, October 2002
	C80	CELGENE CORPORATION, "Blood reports Revimid™ has anti-tumor activity in patients with relapsed and refractory multiple myeloma," Press Release, November 1, 2002
	C81	CELGENE CORPORATION, "Celgene provides update on clinical pipeline. Celgene Announces first target indication for ACTIMID™, CC-8490. SelCID™ program to advance based on results from Phase I/II trial of CC-1088. First JNK inhibitor successfully completes phase I trial," Press Release, January 2003
	C82	CELGENE CORPORATION, "Celgene Corporation announces fourth quarter and full year results for 2002," Press Release, January 2003

	C83	CELGENE CORPORATION, "Celgene receives fast track status from FDA for Revimid™ in multiple myloma," Press Release, February 2003
	C84	CELGENE CORPORATION, "Celgene receives fast track status from FDA for Revimid™ in myelodysplastic syndromes," Press Release, April 2003
	C85	CELGENE CORPORATION, "New Revimid™ clinical data shows potential as novel approach to treating myelodysplastic syndromes (MDS)," Press Release, May 2003
	C86	CELGENE CORPORATION, "Celgene corporation reports strong operating performance in second quarter as total sales increase 100 percent and profits rise," Press Release, July 2003
	C87	CELGENE CORPORATION, "Celgene corporation reports record operating performance in third quarter as total revenue increases 117% and profits rise," Press Release, October 2003
	C88	CELGENE CORPORATION, "Celgene corporation advances ACTIMID™ (CC-4047) into phase II trial for prostate cancer," Press Release, October 2003
	C89	CELGENE CORPORATION, "Additional clinical data presented on Revimid™ in myelodysplastic syndromes at the American Society of Hematology 45 <sup>th</sup> annual meeting," Press Release, December 2003
	C90	CELGENE CORPORATION, "Celgene corporation reviews 2003 achievements and announces 2004 financial outlook," Press Release, January 2004
	C91	CELGENE CORPORATION, "Revlimid™ receives orphan drug designation from the European commission for multiple myeloma," Press Release, February 2004
	C92	CELGENE CORPORATION, "Revlimid™ receives orphan drug designation from the European commission for myelodysplastic syndromes," Press Release, March 2004
	C93	CELGENE CORPORATION, "Celgene corporation reports record operating performance in first quarter with strong revenue growth and profits," Press Release, April 2004
	C94	CELGENE CORPORATION, "Celgene announces plans to stop phase III trials in melanoma due to lack of efficacy," Press Release, April 2004
	C95	DALGLEISH, et al., "New thalidomide analogues; anti-cancer, anti-angiogenic and immunostimulatory," <i>British Journal of Cancer</i> , 2001, 85 (1)25
	C96	DALGLEISH et al., "Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma," <i>British Journal of Cancer</i> , 2003, 88(Suppl I), S25-S54
	C97	DAVIES et al., "Thalidomide (Thal) and immunomodulatory derivatives (IMiDs) augment natural killer (NK) cell cytotoxicity in multiple myeloma(MM)," Abstract # 3617, <i>American Society of Hematology</i> , December 1-5, 2000
	C98	DAVIES et al., "Thalidomide (Thal) and immunomodulatory derivatives (IMiDs) augment natural killer (NK) cell cytotoxicity in multiple myeloma ~MM)," Abstract # P222, <i>VIIIth International Myeloma Workshop</i> , May 4-8, 2001
	C99	DIBBS et al., "Thalidomide and thalidomide analogs suppress TNF $\alpha$ secretion by myocytes," Abstract # 1284, <i>Circulation</i> , 1998
	C100	DIMOPOULOS et al., "Results of thalidomide and IMiDs in multiple myeloma," Abstract # P12.1.4, <i>International Multiple Myeloma Workshop</i> , May 23-27, 2003
	C101	DIMOPOULOS et al., "Treatment of plasma cell dyscrasias with thalidomide and its derivatives," <i>Journal of Clinical Oncology</i> , Dec. 1, 2003, 21 (23)4444-4454
	C102	DIMOPOULOS et al., "Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 Study (MM-010)," Abstract # 6, <i>American Society of Hematology</i> , Dec. 10-13, 2005
	C103	DREDGE et al., "A costimulatory thalidomide analog enhances the partial anti-tumor immunity of an autologous vaccination in a model of colorectal cancer, Abstract # 491, <i>American Association for Cancer Research</i> , April 6-10, 2002
	C104	DREDGE et al., "Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy," <i>Cancer Immunol. Immunother.</i> , 2002, 51:521-531
	C105	DREDGE et al., "Immunological effects of thalidomide and its chemical and functional analogs," <i>Critical Reviews in Immunology</i> , 2002, 22 (5&6):425-437
	C106	DREDGE et al., "Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity <sup>1</sup> ," <i>The Journal of Immunology</i> , 2002, 168:4914-4919
	C107	DREDGE et al., "Recent developments in antiangiogenic therapy," <i>Expert Opin. Biol. Ther.</i> , 2002, 2 (8):953-966
	C108	DREDGE et al., "Angiogenesis inhibitors in cancer therapy," <i>Current Opinion in Investigational Drugs</i> , 2003, 4 (6):667-674
	C109	DREDGE et al., "Thalidomide analogs as emerging anti-cancer drugs," <i>Anti-Cancer Drugs</i> , 2003, 14:331-335
	C110	FICKENTSCHER et al., "Stereochemical properties and teratogenic activity of some tetrahydrophthalimides," <i>Molecular Pharmacology</i> , 1976, 13:133-141
	C111	GALUSTIAN et al., "Thalidomide-derived immunomodulatory drugs as therapeutic agents," <i>Expert Opin. Biol. Ther.</i> , 2004, 4 (12):1-8
	C112	GLASPY et al., "The potential role of thalidomide and thalidomide analogs in melanoma," <i>Clinical Advances in Hematology &amp; Oncology</i> , 2004, 1-7
	C113	GUPTA et al., "Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications," <i>Leukemia</i> , 2001, 15:1950-1961
	C114	HAYASHI et al., "Mechanisms whereby immunomodulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity," <i>Blood</i> , Abstract #3219, Dec. 6-10, 2002, <i>American Society of Hematology</i>
	C115	He, W., et al., 1993, Abstract of papers, 206th American Chemical Society, Chicago, IL; Med. Chem., paper 216

C116	HELM et al., "Comparative teratological investigation of compounds of structurally and pharmacologically related to thalidomide," <i>Arzneimittel Forschung/Drug Research</i> , 1981, 31 (1):941-949
C117	HERNANDEZ-ILLIZALITURR et al., "Addition of immunomodulatory drugs CC5013 or CC4047 to rituximab enhances anti-tumor activity in a severe combined immunodeficiency (SCID) mouse lymphoma model," <i>Abstract # 235, American Society of Hematology</i> , December 6-9, 2003
C118	HIDESHIMA et al., "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy," <i>Blood</i> , 2000, 96:2943-2950, <i>American Society of Hematology</i>
C119	HIDESHIMA et al., "Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy," <i>Abstract 1313, American Society of Hematology</i> , December 1-5, 2000
C120	HUNT et al., "Markers of endothelial and haemostatic activation in the use of CC-4047, a structural analogue of thalidamide, in relapsed myeloma," <i>Blood, Abstract # 3216, Dec. 6-10, 2002, American Society of Hematology</i>
C121	HUSSEIN et al., "Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and Revlimid (DVd-R) a phase I/II trial in advanced relapsed/refractory multiple myeloma (Rmm) patients," <i>Blood, Abstract #208, American Society of Hematology</i> , Dec. 4-7, 2004
C122	HWU et al., "Thalidomide and its analogues in the treatment of metastatic melanoma," <i>Chemotherapy Foundation Symposium, Abstract #44, 2002</i>
C123	KYLE, "Current therapy of multiple myeloma," <i>Internal Medicine</i> , 2002, 41 (3):175-180
C124	KYLE et al., "Multiple myeloma," <i>New England Journal of Medicine</i> , 2004, 351:1860-1873
C125	LEBLANC et al., "Immunomodulatory drug costimulates T cells via the B7-CD28 pathway," <i>Blood</i> , 2004, 103:1787-1790, <i>American Society of Hematology</i>
C126	LENTZSCH et al., "In vivo activity of thalidomide and immunomodulatory drugs against multiple myeloma," <i>VIIth International Myeloma Workshop, Abstract #P225, May 4-8, 2001</i>
C127	LENTZSCH et al., "Immunomodulatory derivative of thalidomide (IMiD CC-4047) determine the lineage commitment of hematopoietic progenitors by down regulation of GATA-1 and modulation of cytokine secretion," <i>Abstract # 3073, American Society of Hematology</i> , December 6-9, 2003
C128	LENTZSCH et al., "Immunomodulatory derivative of thalidomide (IMiD CC-4047) down regulates CAAT/enhancer-binding protein <sup>β</sup> (C/EBP <sup>β</sup> ) in multiple myeloma (MM)," <i>Abstract # 3456, American Society of Hematology</i> , December 6-9, 2003
C129	LUZZIO et al., "Thalidomide analogues: derivatives of an orphan drug with diverse biological activity," <i>Expert Opin. Ther. Patents</i> , 2004, 14 (2):215-229
C130	MAN et al., "α- Fluoro-substituted thalidomide analogues," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 13, 2003, 3415-3417
C131	MARRIOTT et al., "Immunotherapeutic and antitumour potential of thalidomide analogues," <i>Expert Opin. Biol. Ther.</i> , 2001, 1 (4):1-8
C132	MARRIOTT et al., "New thalidomide analogues; anti-cancer, anti-angiogenic and immunostimulatory," <i>British Journal of Cancer</i> , 85:25, July 6, 2001
C133	MARRIOTT et al., "Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells," <i>Clin. Exp. Immunol.</i> , 2002, 130:75-84
C134	MARRIOTT et al., "A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins <sup>1</sup> ," <i>Cancer Research</i> , 2003, 63:593-599
C135	MARRIOTT et al., "Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents," <i>Current Drug Targets - Immune, Endocrine &amp; Metabolic Disorders</i> , 2003, 3:181-186
C136	MASELLIS et al., "Changes in gene expression in bone marrow mesenchymal progenitor cells as a consequence of IMiD therapy in multiple myeloma patients," <i>Blood, Abstract # 1548, Dec. 7-11, 2001, American Society of Hematology</i>
C137	MCCARTY, "Thalidomide may impede cell migration in primates by down-regulating integrin β-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis," <i>Medical Hypotheses</i> , 1997, 49:123-131
C138	MITSIADES et al., "Apoptic signaling induced by immunomodulatory thalidomide analogs (Imids) in human multiple myeloma cells: therapeutic implications," <i>Abstract # 3224, Dec. 7-11, 2001, American Society of Hematology</i>
C139	MITSIADES et al., "Apoptic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications," <i>Blood</i> , 2002, 99:4525-4530, <i>American Society of Hematology</i>
C140	MITSIADES et al., "CC-5013 Celgene," <i>Current Opinion in Investigational Drugs</i> , 2004, 5 (6):635-647
C141	MOUTOUH et al., "Novel immunomodulatory drugs (IMiDs <sup>®</sup> ): A potential, new therapy for β-hemoglobinopathies," <i>Abstract # 3740, American Society of Hematology</i> , December 4-7, 2004
C142	PATTEN et al., "The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047)," <i>Abstract # 1640, American Society of Hematology</i> , December 6-9, 2003
C143	PAYVANDI et al., "Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines," <i>Blood, Abstract #2487, Dec.1-5, 2000, American Society of Hematology</i>
C144	PAYVANDI et al., "The thalidomide analogs IMiDs enhance expression of CD69 stimulatory receptor on natural killer cells," <i>Abstract # 1793, American Association for Cancer Research</i> , March 24-28, 2001
C145	PAYVANDI et al., "Thalidomide analogs IMiDs inhibit expression of cyclooxygenase-2 in multiple myeloma cell line and LPS stimulated PBMCs," <i>Blood, Abstract # 2689, Dec. 7-11, 2001, American Society of Hematology</i>
C146	PAYVANDI et al., "Thalidomide and IMiDS inhibit microvessel formation from human arterial rings in the absence of human liver microsomes," <i>Blood, Abstract # 5046, Dec. 6-10, 2002, American Society of Hematology</i>
C147	PAYVANDI et al., "CC-5013 inhibits the expression of adhesion molecules ICAM-1 and CD44 and prevents metastasis of B16 F10 mouse melanoma cells in an animal model," <i>American Society of Clinical Oncology, Abstract # 992, 2003</i>

C148	PAYVANDI et al., "Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF- $\alpha$ , IL-1 $\beta$ , and LPS-stimulated human PBMC in a partially IL-10-dependent manner," <i>Cellular Immunology</i> , 2004, 81-88
C149	RAJE et al., "Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma," <i>Blood</i> , Dec. 15, 2004, 104 (13)4188-4193
C150	RAJKUMAR et al., "Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma," <i>Blood</i> , Dec. 15, 2005, 106 (13)4050-4053
C151	RICHARDSON et al., "A Phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM)," <i>Blood, Abstract #3225</i> , Dec. 7-11, 2001, <i>American Society of Hematology</i>
C152	RICHARDSON et al., "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma," <i>Blood</i> , 2002 100:3063-3067, <i>American Society of Hematology</i>
C153	RICHARDSON et al., "A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM)," <i>Blood, Abstract # 825</i> , <i>American Society of Hematology</i> , Dec. 6-9, 2003
C154	RICHARDSON et al., "Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma," <i>Journal of Clinical Oncology</i> , 2004, 22(16) 3212-3214
C155	RICHARDSON et al., "A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results," <i>10<sup>th</sup> International Myeloma Workshop</i> , April 10-14, 2005
C156	RICHARDSON et al., "Novel biological therapies for the treatment of multiple myeloma," <i>Best Practice &amp; Research Clinical Haematology</i> , 2005, 18 (4):619-634
C157	RICHARDSON et al., "A phase 1 trial of lenalidomide (REVLIMID <sup>®</sup> ) with bortezomib (VELCADE <sup>®</sup> ) in relapsed and refractory multiple myeloma," <i>Blood, Abstract # 365</i> , <i>American Society of Hematology</i> , Dec. 10-13, 2005
C158	RUBIN et al., "Principles of cancer treatment-1," 2003, 12 ONCO IV 1
C159	SCHAFFER et al., "Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305(3)1222-1232
C160	SCHEY et al., "A phase I study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma," <i>International Society for Experimental Hematology, Abstract #248</i> , 2002
C161	SHAUGHNESSY et al., "Global gene expression analysis shows loss of C-MYC and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD," <i>Abstract # 2485</i> , <i>The American Society of Hematology</i> , December 1-5, 2000
C162	SHIRE et al., "TNF- $\alpha$ inhibitors and rheumatoid arthritis," <i>Exp. Opin. Ther. Patents</i> , 1998, 8 (5):531-544
C163	SORBERA et al., "CC-5013. Treatment of multiple myeloma. Treatment of Melanoma. Treatment of myelodysplastic syndrome. Angiogenesis inhibitor. TNF- $\alpha$ production inhibitor," <i>Drugs of the Future</i> , 2003, 28(5):425-431
C164	STREETLY et al., "Thalidomide analogue CC-4047 is effective in the treatment of patients with relapsed and refractory multiple myeloma (MM) and induces T-cell activation and IL-12 production," <i>Abstract # 367</i> , <i>International Multiple Myeloma Workshop</i> , May 23-27, 2003
C165	STREETLY et al., "Changes in neutrophil phenotype following the administration of CC-4047 (Actimid) to patients with multiple myeloma," <i>Abstract # 2543</i> , <i>American Society of Hematology</i> , December 6-9, 2003
C166	STREETLY et al., "An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma," <i>Abstract #829</i> , <i>American Society of Hematology</i> , December 6-9, 2003
C167	TEO et al., "A phase I, single-blind, placebo-controlled, ascending single oral dose, safety, tolerability and pharmacokinetic study of CDC-501, a novel immunomodulatory- oncologic agent, in healthy male subjects with a comparison of fed and fasted," <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71 (2)93
C168	TEO et al., "Chiral inversion of the second generation IMiD <sup>™</sup> CC-4047 (ACTIMID <sup>™</sup> ) in human plasma and phosphate-buffered saline," <i>Chirality</i> , 2003, 15:348-351
C169	THERTULIEN et al., "Hybrid MEL/DT PACE autotransplant regimen for Multiple Myeloma (MM)- safety and efficacy data in pilot study of 15 patients," <i>Blood, Abstract # 2869</i> , <i>American Society of Hematology</i> , Dec. 7-11, 2001
C170	TOHNYA et al., "A phase I study of oral CC-5013 (lenalidomide, Revlimid <sup>™</sup> ), a thalidomide derivative, in patients with refractory metastatic cancer," <i>Clinical Prostate Cancer</i> , 2004, 2:241-243
C171	TRICOT et al., "Angiochemotherapy (ACT) for multiple myloma (MM) with DT-PACE results in a high response rate, but in contrast to tandem transplants with melphalan does not affect durable disease control," <i>Blood, Abstract # 3531</i> , <i>American Society of Hematology</i> , Dec. 7-11, 2001
C172	TSENOVA et al., "Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis," <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46 (6)1887-1895
C173	WEBER, "Lenalidomide (CC-5013, Revlimid <sup>™</sup> ) and other ImiDs," <i>Abstract # PL5.02</i> , <i>International Multiple Myeloma Workshop</i> , April 10-14, 2005
C174	WEBER et al., "A multicenter, randomized, parallel-group, double-blind, placebo-controlled study of lenalidomide plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma," <i>Abstract # PO.738</i> , <i>International Multiple Myeloma Workshop</i> , April 10-14, 2005
C175	YE et al., "Novel IMiD drugs enhance expansion and regulate differentiation of human cord blood CD34+ cells with cytokines," <i>Blood, Abstract #4099</i> , <i>American Society of Hematology</i> , Dec. 6-10, 2002
C176	ZANGARI et al., "Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (Pts) treated with thalidomide (Thal): The Arkansas Experience," <i>Blood, Abstract # 681</i> , <i>American Society of Hematology</i> , Dec. 7-11, 2001
C177	ZANGARI et al., "Revimid 25 mg (REV 25) x 20 versus 50 mg (REV 50) x 10 q 28 days with bridging of 5 mg x 10 versus

	10 mg x 5 as post-transplant salvage therapy for multiple myeloma (MM)," <i>Blood, Abstract # 1642, American Society of Hematology</i> , Dec. 6-9, 2003
C178	ZELDIS et al., "Potential new therapeutics for Waldenstrom's macroglobulinemia," <i>Seminars in Oncology</i> , 2003, 30 (2):275-281
C179	ZHANG et al., "CC-5079, a novel microtubule and TNF- $\alpha$ inhibitor with anti-angiogenic and antimetastasis activity," <i>Abstract # B012, International Conference on Molecular Targets and Cancer Therapeutics</i> , Nov. 17-21, 2003
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.